Related Experiment Video
Updated: Jul 14, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
The obligation to provide antiretroviral treatment in HIV prevention trials
Bernard Lo1, Nancy Padian, Mark Barnes
1Program in Medical Ethics, Center for AIDS Prevention Studies and Division of General Internal Medicine, University of California San Francisco, San Francisco, CA, USA.
Abstract:
Providing antiretroviral therapy (ART) to participants who seroconvert during HIV prevention trials in developing countries is an ethical expectation. Promising treatment to the few seroconverters widens disparities within a resource-poor country and would be unjust. Such an assurance should be done in a way that also improves access to ART for others in the country. US funds for ART in poor countries from the PEPFAR should be available to all countries that host HIV prevention and clinical trials.
Related Concept Videos
Retrovirus Life Cycles
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Antiviral Nucleoside Inhibitors
Bioequivalence studies: Biowaivers
Sexually Transmitted Infections

